# Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer

> **NCT06029088** · — · COMPLETED · sponsor: **Ankara Etlik City Hospital** · enrollment: 616 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06029088
- **Lead sponsor:** Ankara Etlik City Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2023-05-21
- **Final completion:** 2023-06-16
- **Target enrollment:** 616 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06029088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06029088, "Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06029088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*